Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved]
The spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this “evolving crisis” is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-08-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/7-1347/v1 |
| _version_ | 1818042841907068928 |
|---|---|
| author | Zoi Dorothea Pana Theoklis Zaoutis |
| author_facet | Zoi Dorothea Pana Theoklis Zaoutis |
| author_sort | Zoi Dorothea Pana |
| collection | DOAJ |
| description | The spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this “evolving crisis” is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between “Scylla and Charybdis”: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization’s warning against a “post antibiotic era”, health-care providers are at a critical standpoint to find a “balance” between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data. |
| first_indexed | 2024-12-10T08:52:44Z |
| format | Article |
| id | doaj.art-3c7503c9f90b4b6391dee01236a28b1a |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-10T08:52:44Z |
| publishDate | 2018-08-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-3c7503c9f90b4b6391dee01236a28b1a2022-12-22T01:55:32ZengF1000 Research LtdF1000Research2046-14022018-08-01710.12688/f1000research.14822.116132Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved]Zoi Dorothea Pana0Theoklis Zaoutis1Infectious Diseases Department, 3rd Department of Pediatrics, Hippokration General Hospital Aristotle University, Thessaloniki, GreeceInfectious Diseases Department, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAThe spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this “evolving crisis” is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between “Scylla and Charybdis”: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization’s warning against a “post antibiotic era”, health-care providers are at a critical standpoint to find a “balance” between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data.https://f1000research.com/articles/7-1347/v1 |
| spellingShingle | Zoi Dorothea Pana Theoklis Zaoutis Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved] F1000Research |
| title | Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved] |
| title_full | Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved] |
| title_fullStr | Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved] |
| title_full_unstemmed | Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved] |
| title_short | Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; referees: 2 approved] |
| title_sort | treatment of extended spectrum β lactamase producing enterobacteriaceae esbls infections what have we learned until now version 1 referees 2 approved |
| url | https://f1000research.com/articles/7-1347/v1 |
| work_keys_str_mv | AT zoidorotheapana treatmentofextendedspectrumblactamaseproducingenterobacteriaceaeesblsinfectionswhathavewelearneduntilnowversion1referees2approved AT theokliszaoutis treatmentofextendedspectrumblactamaseproducingenterobacteriaceaeesblsinfectionswhathavewelearneduntilnowversion1referees2approved |